LAS 191351Alternative Names: LAS191351
Latest Information Update: 09 Sep 2016
At a glance
- Originator Almirall S.A.
- Class Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic M3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic obstructive pulmonary disease
Most Recent Events
- 27 Apr 2016 Phase-I clinical trials in Chronic obstructive pulmonary disease in Spain (Inhalation) (Almirall pipeline, April 2016)